Sign In
Last checked at 
11 May 2011 11:17
Press Release | 11 May 2011 |
Syntopix Group plc
("Syntopix" or "the Company")
Director's Dealing
Syntopix Group plc (AIM:SYN), the speciality pharmaceutical research and development company focused on topical antimicrobial innovations for products in the medicine and consumer healthcare markets, has today been notified that, on 10 May 2011, Tom Bannatyne, Chairman of the Company, acquired 140,000 ordinary shares of 10p each in the Company, at a price of 48p per share. Following this purchase Mr Bannatyne has a beneficial interest in 646,467 ordinary shares representing approximately 6.03 per cent. of the Company's issued share capital.
- Ends -
For further information, please contact:
Syntopix Group plc | |
Dr Stephen Jones, Chief Executive Officer | +44 (0)845 125 9204 |
Tom Bannatyne, Chairman | www.syntopix.com |
Zeus Capital Ltd | |
Alex Clarkson | Tel: +44(0)161 831 1512 |
Tom Rowley | www.zeuscapital.co.uk |
XCAP Securities Plc | |
Karen Kelly/Jon Belliss/Parimal Kumar | Tel: +44(0) 207 101 7070 |
www.xcapgroup.co.uk |
Media enquiries:
Abchurch Communications | |
Sarah Hollins/Adam Michael | Tel: +44 (0) 20 7398 7708 |
adam.michael@abchurch-group.com | www.abchurch-group.com |
Notes to editors
About Syntopix Group plc
Syntopix is a specialised research and development business, focusing on topical antimicrobial innovations for products in consumer healthcare and pharmaceutical markets. The Group was founded in 2003 as a spin-out from the University of Leeds.
Syntopix has a robust pipeline, with a growing library of over 3,000 compounds screened and characterised for antimicrobial activity. Its strategy is to seek to reduce the risks and costs of drug discovery and development by discovering novel uses for known compounds and combinations of compounds, which have established safety profiles.
From this library, Syntopix has identified compounds that have multiple potential uses across a number of large consumer healthcare markets including skincare, hair-care and oral health. The Group's development focus is on taking these lead antimicrobial compounds through to clinical studies and subsequent licensing. Syntopix has developed strong working relationships with a number of major consumer healthcare companies and is now actively seeking to out-license these products to commercial partners. The Group adopts an ongoing filing process that has resulted in 24 core patents/applications.
The Group is based at the Institute of Pharmaceutical Innovation in Bradford, giving access to the expertise in skin biology, formulation and toxicology at the Universities of Bradford and Leeds.
Syntopix' shareholders include IP Group plc, The Wellcome Trust Limited, The University of Leeds and Ridings Early Growth Investment Company Limited. Syntopix joined the AIM market of the London Stock Exchange in March 2006.
For more information, please visit our website at www.syntopix.com.
Follow the stocks
